hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06290622, orgStudyIdInfo id: IRB300012414 (UAB23136), briefTitle: PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-30, primaryCompletionDateStruct date: 2026-06-30, completionDateStruct date: 2028-01-31, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-04-24, sponsorCollaboratorsModule leadSponsor name: University of Alabama at Birmingham, class: OTHER, descriptionModule briefSummary: This study is investigating the optimal dose and the advantage in combining investigational immunotherapy drugs known as Retifanlimab, INCAGN02385 and INCAGN02390 to improve the responses to CAR T-cell therapy. Additionally, the study will investigate that triple checkpoint blockade of PD-1, TIM-3 and LAG-3 molecules will overcome CAR T-cell therapy resistance in patients with suboptimal responses., conditionsModule conditions: Diffuse Large B Cell Lymphoma, conditions: Lymphoma, B-Cell, conditions: Lymphoma, Follicular, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 18, type: ESTIMATED, armsInterventionsModule interventions name: Retifanlimab, INCAGN02385, INCAGN02390, outcomesModule primaryOutcomes measure: Identify the optimal biological dose (OBD) for Retifanlimab in combination with INCAGN02385 and INCAGN02390 in relapsed/refractory DLBCL., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: University of Alabama at Birmingham, city: Birmingham, state: Alabama, zip: 35294, country: United States, contacts name: Margaret Thomas, role: CONTACT, email: margaretannthomas@uabmc.edu, contacts name: Mayur Narkhede, MD, role: PRINCIPAL_INVESTIGATOR, contacts name: Amitkumar Mehta, MD, role: SUB_INVESTIGATOR, contacts name: Lauren Shea, MD, role: SUB_INVESTIGATOR, contacts name: Gaurav Goyal, MD, role: SUB_INVESTIGATOR, geoPoint lat: 33.52066, lon: -86.80249, hasResults: False
protocolSection identificationModule nctId: NCT06290609, orgStudyIdInfo id: 72799, briefTitle: Vibrotactile Coordinated Reset for Spasticity After Spinal Cord Injury, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03-15, primaryCompletionDateStruct date: 2024-06-15, completionDateStruct date: 2024-06-15, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Stanford University, class: OTHER, descriptionModule briefSummary: The purpose of our study is to evaluate vibrotactile Coordinated Reset (vCR) and its effects on spasticity symptoms in incomplete spinal cord injured patients. vCR will be administered with a device called the Stanford CR Glove. vCR is expected to provide patients with a non-invasive alternative to the most widely used treatments such as oral baclofen and or deep brain stimulation. Patients will be followed for three months and will be asked to come to the lab for clinical testing 4 times during this period. A total of 30 patients will be included in the study., conditionsModule conditions: Spasticity, Muscle, conditions: Spinal Cord Injuries, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: A single group of participants who will receive active treatment with the experimental stimulation device will be studied., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Vibrotactile Coordinated Reset, outcomesModule primaryOutcomes measure: Change from baseline in spasticity with the Modified Ashworth Scale (MAS) at 2 hours, 1 week, 4 weeks, and 12 weeks., eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Stanford University, city: Stanford, state: California, zip: 94305, country: United States, contacts name: Peter Tass, MD, PhD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.42411, lon: -122.16608, hasResults: False
protocolSection identificationModule nctId: NCT06290596, orgStudyIdInfo id: MSR/AZAST/AIP029/21/222/8/2023, briefTitle: Vasopressin Versus Tranexamic Acid for Control of Blood Loss Related to Abdominal Hysterectomy, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2024-10-01, completionDateStruct date: 2024-10-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Al-Azhar University, class: OTHER, descriptionModule briefSummary: To find the best option to reduce blood loss related to abdominal hysterectomy (AH), the present randomized double-blinded study sought to compare the effects of locally administered vasopressin (VP) and tranexamic acid (TXA) on blood loss in women submitted to AH for benign lesions., conditionsModule conditions: Uterine Surgery, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: PREVENTION, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 387, type: ESTIMATED, armsInterventionsModule interventions name: Vasopressin, interventions name: Tranexamic acid, interventions name: Saline, outcomesModule primaryOutcomes measure: blood loss, eligibilityModule sex: FEMALE, minimumAge: 20 Years, maximumAge: 60 Years, stdAges: ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06290583, orgStudyIdInfo id: Prilocaine in cesarean section, briefTitle: Comparing the Effect of Spinal Bupivacaine Versus Spinal Prilocaine on Maternal Blood Pressure in Cesarean Section, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05, primaryCompletionDateStruct date: 2024-11, completionDateStruct date: 2024-12, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: South Valley University, class: OTHER, descriptionModule briefSummary: one of the most common complications associated with spinal anesthesia is hypotension, which can have adverse effects on both the mother and the fetus. The present study compare prilocaine versus bupivacaine in spinal anesthesia on hypotension and there effect on maternal outcomes., conditionsModule conditions: Spinal Anesthetics Causing Adverse Effects in Therapeutic Use, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: Bupivacaine, interventions name: Prilocaine, outcomesModule primaryOutcomes measure: Maternal arterial blood pressure, secondaryOutcomes measure: Evaluation of duration of motor block, secondaryOutcomes measure: Total dose of ephedrine, eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 35 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06290570, orgStudyIdInfo id: 23-007685, briefTitle: A Study of Artificial Intelligence ECG With ECG Devices to Detect Hypertrophic Cardiomyopathy Distinct From Athlete's Heart, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2025-09, completionDateStruct date: 2025-09, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-04-03, sponsorCollaboratorsModule leadSponsor name: Mayo Clinic, class: OTHER, descriptionModule briefSummary: The purpose of this study is to evaluate the AI-ECG algorithm for HCM in detecting HCM and in differentiating it from athlete's heart using not only the standard 12-lead ECG, but also ECGs obtained with the Apple Watch and Alivecor KardiaMobile devices., conditionsModule conditions: Hypertrophic Cardiomyopathy, conditions: Athlete Heart, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 300, type: ESTIMATED, armsInterventionsModule interventions name: 12-Lead ECG, interventions name: Apple Smart Watch Single Lead ECG, interventions name: AliveCor KardiaMobile 6-Lead ECG, outcomesModule primaryOutcomes measure: Distribution of AI-ECG probabilities in HCM, primaryOutcomes measure: Comparative diagnostic performance between tracings obtained from different devices, secondaryOutcomes measure: Distribution of AI-ECG probabilities in Athlete's Heart, secondaryOutcomes measure: Correlation with false negative AI ECG result, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Mayo Clinic in Rochester, city: Rochester, state: Minnesota, zip: 55905, country: United States, contacts name: Heart Rhythm Services Research Team, role: CONTACT, phone: 507-255-0774, contacts name: Konstantinos Siontis, MD, role: CONTACT, phone: (507) 255-1051, email: Siontis.Konstantinos@mayo.edu, contacts name: Konstantinos Siontis, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 44.02163, lon: -92.4699, hasResults: False
protocolSection identificationModule nctId: NCT06290557, orgStudyIdInfo id: 2023-507737-17-00, briefTitle: First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133, acronym: HY-133, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-07-01, primaryCompletionDateStruct date: 2025-07-01, completionDateStruct date: 2026-07-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-05, sponsorCollaboratorsModule leadSponsor name: University Hospital Tuebingen, class: OTHER, descriptionModule briefSummary: In this clinical trial we will test a new approach for decolonization of S. aureus.As innovative product HY-133 a recombinant chimeric bacteriophage endolysin will be sprayed in both nostrils of healthy subjects once or five times in one day. To avoid possible bias the subjects will be randomized 3:2 verum vs placebo, moreover the subject as well as the investigator will be blinded to the group assigned., conditionsModule conditions: Staphylococcus Aureus, designModule studyType: INTERVENTIONAL, phases: PHASE1, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: QUADRUPLE, whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 52, type: ESTIMATED, armsInterventionsModule interventions name: HY_133, interventions name: Placebo, outcomesModule primaryOutcomes measure: ADRs/AEs/SAEs occurring from the time of application until the final study visit (Day15) for each subject, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06290531, orgStudyIdInfo id: CEBD-CU-2023-11-12, briefTitle: Different Methods for Reducing Buccal Infiltration Local Anesthesia Injection Pain, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-16, primaryCompletionDateStruct date: 2023-09-28, completionDateStruct date: 2023-09-28, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: Local anesthetic injection is considered one of the most annoying dental procedures. The use of topical anesthesia is considered a routine procedure in the dental clinic especially for children. However, the taste and application procedure of the topical gel may not be pleasant for all children.The introduction of the Buzzy device is considered a distraction measure in the medical field. Alanazi et al., 2019, studied the effect of using the Buzzy device with cold and vibration compared to the conventional infiltration technique using 30-gauge needle. They concluded that the use of the Buzzy device resulted in better patients' acceptance and significantly lower Wong-Baker scores.Ballard et al., 2019, mentioned in their systematic review the efficacy of the Buzzy device for pain management during needle-related procedures, they concluded that the use of the device may be promising. Ghaderi et al., 2013, evaluated the effect of cooling the injection site on pain perception before infiltration of local anesthetics. They found that cooling the injection site before infiltration of local anesthetics in the buccal mucosa for 1 min, reduced pain perceived by pediatric patients., conditionsModule conditions: Dental Caries in Children, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: OTHER, maskingInfo masking: NONE, maskingDescription: The statistician was only blinded for data analysis. But it was not feasible to blind the participant, investigator or the outcome assessor due to the nature of the study., enrollmentInfo count: 96, type: ACTUAL, armsInterventionsModule interventions name: Buzzy device (cold and vibration), interventions name: Buzzy device (vibration only), interventions name: precooling, interventions name: Flavored Benzocaine topical anesthetic gel 20%, outcomesModule primaryOutcomes measure: Patient reported pain during needle injection, secondaryOutcomes measure: Child behaviour during needle injection, secondaryOutcomes measure: Heart rate, secondaryOutcomes measure: Oxygen saturation, secondaryOutcomes measure: Child and parent satisfaction, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Pediatric Dentistry and Dental Public Health, Faculty of Dentistry, Cairo University, city: Cairo, zip: 11559, country: Egypt, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06290492, orgStudyIdInfo id: AHMU-tDCS-insomnia, briefTitle: Clinical Efficacy and Mechanism of High Definition tDCS Based on dmPFC in the Intervention of Chronic Insomnia, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-05-01, primaryCompletionDateStruct date: 2023-12-30, completionDateStruct date: 2024-11-01, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: WANG KAI, class: OTHER, descriptionModule briefSummary: To investigate the intervention effect of transcranial direct current stimulation (tDCS) on subjective and objective insomnia symptoms and daytime function of chronic insomnia patients., conditionsModule conditions: Chronic Insomnia, conditions: Transcranial Direct Current Stimulation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: TRIPLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 45, type: ESTIMATED, armsInterventionsModule interventions name: transcranial direct current stimulation, interventions name: sham transcranial direct current stimulation, outcomesModule primaryOutcomes measure: subjective sleep quality assessed by the PSQI, primaryOutcomes measure: subjective sleep quality assessed by the ISI, primaryOutcomes measure: daytime sleepiness assessed by the FFS, primaryOutcomes measure: daytime sleepiness assessed by the ESS, primaryOutcomes measure: objective sleep quality assessed by the PSG, secondaryOutcomes measure: emotional symptoms assessed by the HAMA, secondaryOutcomes measure: emotional symptoms assessed by the HAMD, eligibilityModule sex: ALL, minimumAge: 15 Years, maximumAge: 65 Years, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Anhui Medical University, status: RECRUITING, city: Hefei, state: Anhui, country: China, contacts name: Kai Wang, PhD, role: CONTACT, phone: +86-0551-62923704, email: wangkai1964@126.com, contacts name: Chengjuan Xie, role: CONTACT, phone: +8615656989777, email: xie_chengjuan@126.com, geoPoint lat: 31.86389, lon: 117.28083, hasResults: False
protocolSection identificationModule nctId: NCT06290479, orgStudyIdInfo id: 20358, briefTitle: A Three-Group Study to Examine the Efficacy of the Air up® Drinking System at Improving Hydration and Associated Health Outcomes, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-02-15, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: air up GmbH, class: INDUSTRY, collaborators name: Citruslabs, descriptionModule briefSummary: A randomized, controlled trial evaluating the air up® drinking system's impact on hydration and health outcomes. Participants will use air up® with Peach, Orangeade, or unscented pods and their effects on drinking habits, and health outcomes will be assessed over 12 weeks., conditionsModule conditions: Water Intake, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: Allocation: Randomized Intervention Model: Parallel Assignment Masking: Triple (Participant, Care Provider, Investigator), primaryPurpose: OTHER, maskingInfo masking: QUADRUPLE, maskingDescription: Masking: Triple (Participant, Care Provider, Investigator), whoMasked: PARTICIPANT, whoMasked: CARE_PROVIDER, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 50, type: ESTIMATED, armsInterventionsModule interventions name: Air Up® Peach Pod, interventions name: Air Up® Orangeade Pod, outcomesModule primaryOutcomes measure: Change in Hydration Habits and Health Outcomes as Measured by the Water Intake Questionnaire and the Hydration-Related Quality of Life Scale, secondaryOutcomes measure: Blood Biomarkers, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 50 Years, stdAges: ADULT, contactsLocationsModule locations facility: Citruslabs, status: RECRUITING, city: Santa Monica, state: California, zip: 90404, country: United States, contacts name: Patrick Renner, MSc, role: CONTACT, email: hello@citruslabs.com, geoPoint lat: 34.01945, lon: -118.49119, hasResults: False
protocolSection identificationModule nctId: NCT06290453, orgStudyIdInfo id: AOGR, briefTitle: The Regulatory Role of miRNA 27 Follistatin Like Protein-1 Gene in Multiple Scelerosis, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-03, primaryCompletionDateStruct date: 2025-03, completionDateStruct date: 2026-03, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-04, sponsorCollaboratorsModule leadSponsor name: Assiut University, class: OTHER, descriptionModule briefSummary: Multiple sclerosis (MS) is a neurodegenerative disease characterized by demyelination of the central nervous system. Young women between the ages of 20 and 40 are primarily targeted by this disabling disorder. Till now there are no sufficient mechanisms to explain the pathophysiology of multiple sclerosis., conditionsModule conditions: Multiple Sclerosis, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_CONTROL, timePerspective: CROSS_SECTIONAL, enrollmentInfo count: 60, type: ESTIMATED, armsInterventionsModule interventions name: micro RNA 27- FLP1 gene expression, interventions name: The Expanded Disability Status Scale (EDSS), interventions name: Electrophysiological assessment:, interventions name: MRI examination MRI brain:, outcomesModule primaryOutcomes measure: • To measure the levels of miR-27 expression and its target gene (FSTL1) in progressive MS and relapsing-remitting multiple sclerosis (RRMS) patients., secondaryOutcomes measure: To correlate the levels of expression of miR-27 expression and its target gene (FSTL1) relative to the severity of symptoms of MD patients., eligibilityModule sex: FEMALE, minimumAge: 20 Years, maximumAge: 45 Years, stdAges: ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06290440, orgStudyIdInfo id: 28/NDGD-HDDD, briefTitle: MEdication Counselling Models for Outpatient oRal antIcoaguLation, acronym: MEMORIAL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06, primaryCompletionDateStruct date: 2025-12, completionDateStruct date: 2026-12, studyFirstPostDateStruct date: 2024-03-04, lastUpdatePostDateStruct date: 2024-03-06, sponsorCollaboratorsModule leadSponsor name: Gia Dinh People Hospital, class: OTHER, descriptionModule briefSummary: The goal of this clinical trial is to investigate whether telepharmacy-led counselling can improve medication adherence, knowledge, and hospitalisation/mortality compared with pharmacist-led counselling in adult outpatients taking oral anticoagulants., conditionsModule conditions: Anticoagulants; Circulating, Hemorrhagic Disorder, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: HEALTH_SERVICES_RESEARCH, maskingInfo masking: NONE, enrollmentInfo count: 360, type: ESTIMATED, armsInterventionsModule interventions name: Telepharmacy-led counselling, interventions name: Pharmacist-led counselling, outcomesModule primaryOutcomes measure: Medication adherence, secondaryOutcomes measure: Knowledge of oral anticoagulants, secondaryOutcomes measure: All-cause hospitalisation, secondaryOutcomes measure: VTE-related hospitalisation, secondaryOutcomes measure: Bleeding-related hospitalisation, secondaryOutcomes measure: All-cause mortality, secondaryOutcomes measure: VTE-related mortality, secondaryOutcomes measure: Bleeding-related mortality, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False